Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

NCT05384496 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Mucosal Melanoma

Interventions

DRUG: Nivolumab and/or Ipilimumab
RADIATION: Stereotactic Body Radiation Therapy (SBRT)
DRUG: axitinib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]